Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$12.54 +8.0%	$10.92	$7.34 ▼ $21.00	$571.12M	1.04	523,360 shs	1.65 million shs
KIDS OrthoPediatrics	$22.76 +4.0%	$21.58	$19.52 ▼ $34.77	$552.77M	1.1	196,795 shs	116,353 shs
NPCE NeuroPace	$9.35 -0.1%	$12.33	$5.45 ▼ $18.98	$306.68M	1.93	188,499 shs	229,910 shs
OBIO Orchestra BioMed	$3.20 +1.3%	$2.99	$2.37 ▼ $8.30	$122.59M	0.61	180,914 shs	58,396 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+2.93%	-3.41%	+19.32%	-24.76%	+27.30%
KIDS OrthoPediatrics	-0.59%	-1.17%	+7.84%	+5.39%	-32.82%
NPCE NeuroPace	+3.31%	-1.99%	-10.09%	-14.44%	+17.59%
OBIO Orchestra BioMed	+2.27%	+4.29%	+4.98%	+10.49%	-60.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.1253 of 5 stars	3.5	1.0	0.0	1.5	2.5	0.6
KIDS OrthoPediatrics	4.1454 of 5 stars	3.4	2.0	3.9	1.8	3.3	0.6
NPCE NeuroPace	2.9539 of 5 stars	3.5	3.0	0.0	0.6	4.2	0.6
OBIO Orchestra BioMed	2.9144 of 5 stars	3.6	5.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$24.50	95.37% Upside
KIDS OrthoPediatrics	2.86	Moderate Buy	$35.83	57.44% Upside
NPCE NeuroPace	3.00	Buy	$17.00	81.82% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	343.75% Upside

Current Analyst Ratings Breakdown

Latest OBIO, KIDS, AXGN, and NPCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	KIDS OrthoPediatrics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$194.52M	2.94	N/A	N/A	$2.36 per share	5.31
KIDS OrthoPediatrics	$212.45M	2.60	N/A	N/A	$14.64 per share	1.55
NPCE NeuroPace	$79.91M	3.84	N/A	N/A	$0.27 per share	34.63
OBIO Orchestra BioMed	$2.64M	46.44	N/A	N/A	$0.87 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.15	N/A	N/A	N/A	-3.68%	-7.09%	-3.67%	8/6/2025 (Estimated)
KIDS OrthoPediatrics	-$37.82M	-$1.75	N/A	N/A	N/A	-19.15%	-7.03%	-5.45%	8/4/2025 (Estimated)
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.42%	-190.84%	-25.08%	8/12/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest OBIO, KIDS, AXGN, and NPCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AXGN AxoGen	$0.06	N/A	N/A	N/A	$52.61 million	N/A
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	N/A	N/A	N/A	$23.08 million	N/A
8/4/2025	Q2 2025	KIDS OrthoPediatrics	-$0.17	N/A	N/A	N/A	$61.40 million	N/A
5/13/2025	Q1 2025	NPCE NeuroPace	-$0.26	-$0.21	+$0.05	-$0.21	$21.85 million	$22.52 million
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.63	4.28	2.65
KIDS OrthoPediatrics	0.21	6.19	2.99
NPCE NeuroPace	2.46	6.63	5.70
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
KIDS OrthoPediatrics	69.05%
NPCE NeuroPace	78.83%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
KIDS OrthoPediatrics	32.70%
NPCE NeuroPace	20.50%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	44.28 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.56 million	Optionable
NPCE NeuroPace	170	32.80 million	26.08 million	Optionable
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable

OBIO, KIDS, AXGN, and NPCE Headlines

Recent News About These Companies

Analysts Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Price Target at $14.20

July 15, 2025 | americanbankingnews.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Buy" by Brokerages

July 12, 2025 | marketbeat.com

Orchestra BioMed (NASDAQ:OBIO) Trading Up 1.7% - Here's What Happened

July 10, 2025 | marketbeat.com

Hedge funds owners may take dramatic actions as Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) recent 14% drop adds to one-year losses

July 2, 2025 | finance.yahoo.com

Orchestra BioMed Confirms Director Elections and Auditor

June 24, 2025 | tipranks.com

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

June 20, 2025 | nasdaq.com

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025 | msn.com

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

June 18, 2025 | globenewswire.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025 | seekingalpha.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.comA

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO, KIDS, AXGN, and NPCE Company Descriptions

AxoGen NASDAQ:AXGN

$12.54 +0.93 (+8.01%)

Closing price 04:00 PM Eastern

Extended Trading

$12.53 -0.01 (-0.09%)

As of 04:31 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

OrthoPediatrics NASDAQ:KIDS

$22.76 +0.88 (+4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$22.76 0.00 (0.00%)

As of 04:20 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

NeuroPace NASDAQ:NPCE

$9.35 -0.01 (-0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$9.36 +0.01 (+0.05%)

As of 04:28 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Orchestra BioMed NASDAQ:OBIO

$3.20 +0.04 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 +0.00 (+0.16%)

As of 04:25 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time